Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Estrogen Receptor-Positive Breast Carcinoma

In brief

This phase II trial tests how well Reishi mushroom extract works in treating fatigue and/or joint/muscle pain (arthralgias/myalgias) in patients with breast cancer on aromatase inhibitors. Fatigue and arthralgias/myalgias are common symptoms in breast cancer patients taking aromatase inhibitors (AI). Given the long duration of AI treatment for some women (up to 10 years), these symptoms can significantly impact quality of life and premature discontinuation of AIs, a beneficial medication. Reishi mushrooms are among several medicinal mushrooms that have been used for hundreds of years, mainly in Asian countries, to help enhance the immune system, reduce stress, improve sleep, and lessen fatigue. Reishi mushroom extracts have not been studied explicitly for treatment-induced arthralgias/myalgias, but have been shown to improve quality of life, muscular strength, pain, and flexibility. Information from this study may help researchers determine the effect of Reishi mushroom extract on fatigue and arthralgias/myalgias in breast cancer patients receiving an AI.

Key facts

Study ID

NCT06028022

Run by

Mayo Clinic

People needed

80

Starts

2023-10-18

Expected to finish

2027-09-15

Last updated by the study team

2026-06-16

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• History of breast cancer, estrogen receptor positive (ER+), Her 2 positive or negative
• Fatigue ≥ 4/10
• Currently post-menopausal (as defined by National Comprehensive Cancer Network (version 4.2024), taking any aromatase inhibitor in the curative setting and planning to be on such for at least 8 weeks after registration. [Patients on concurrent ovarian suppression (such as with leuprolide acetate, goserelin) are allowed]; CDK 4/6 inhibitors abemaciclib, ribociclib ARE allowed
• Prior treatment: last chemotherapy ≥ 90 days prior to randomization (if treated with chemotherapy)
• On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days)
• If on supplements, must be on stable dose with no plan to change; not on or planning any acupuncture or other specific supportive modalities for fatigue or AI arthralgias
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
• White blood cell count (WBC) ≥ 3,000/mm\^3 (obtained ≤ 30 days prior to randomization)
• Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to randomization)
• Platelet count ≥ 100,000/mm\^3 (obtained ≤ 30 days prior to randomization)
• Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 30 days prior to randomization)
• Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 1.2 x ULN (obtained ≤ 30 days prior to randomization)
• Prothrombin time (PT)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (obtained ≤ 30 days prior to randomization)
• Negative pregnancy test done ≤ 7 days prior to registration, for persons on concurrent ovarian suppression only
• Provide informed consent
• Ability to complete questionnaires
• Willing to return to enrolling institution during the active monitoring phase of the study
• Patients who have had a recent surgery or procedure should be healed and cleared by their clinician and/or surgeon per local standards, prior to registration

You may not qualify if…

• Other known uncontrolled medical conditions causing fatigue such as untreated thyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection, autoimmune disease, or active/untreated hepatitis
• Allergy to mushrooms
• On anticoagulation medication or aspirin or having a known bleeding disorder
• On any specific medication for fatigue (e.g., methylphenidate)
• Metastatic cancer diagnosis (history of nodal metastases is allowed)
• Chronic steroid use, unless on physiologic replacement doses
• Current use of any medical mushrooms
• On medications for diabetes
• History of symptomatic hypotension
• Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the following link:
• https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems
• Drugs which exhibit either >20% inhibition or >20% induction of CYP2E1 in vivo, such as: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, \& Theophylline
• Taking olaparib
• Any of the following because this study involves an agent that has unknown genotoxic, mutagenic and teratogenic effects:
• Pregnant persons
• Nursing persons
• Persons on concurrent ovarian suppression who are unwilling to employ adequate contraception (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)
• Planned surgery or procedure during time on study and ≤ 14 days after last dose, due to bleeding risks

Where it is running

• Sanford Worthington Medical Center — Worthington, Minnesota, United States (enrolling)
• Essentia Health Baxter Clinic — Baxter, Minnesota, United States (enrolling)
• Sanford Joe Lueken Cancer Center — Bemidji, Minnesota, United States (enrolling)
• Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota, United States (enrolling)
• Essentia Health Deer River Clinic — Deer River, Minnesota, United States (enrolling)
• Essentia Health Saint Mary's - Detroit Lakes Clinic — Detroit Lakes, Minnesota, United States (enrolling)
• Essentia Health Cancer Center — Duluth, Minnesota, United States (enrolling)
• Essentia Health Ely Clinic — Ely, Minnesota, United States (enrolling)
• Essentia Health Fosston — Fosston, Minnesota, United States (enrolling)
• Fairview Grand Itasca Clinic & Hospital — Grand Rapids, Minnesota, United States (enrolling)
• Essentia Health Hibbing Clinic — Hibbing, Minnesota, United States (enrolling)
• Fairview Range Medical Center — Hibbing, Minnesota, United States (enrolling)
• Essentia Health International Falls Clinic — International Falls, Minnesota, United States (enrolling)
• Mayo Clinic Health Systems-Mankato — Mankato, Minnesota, United States (enrolling)
• Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota, United States (enrolling)
• Essentia Health Moose Lake — Moose Lake, Minnesota, United States (enrolling)
• Essentia Health Park Rapids — Park Rapids, Minnesota, United States (enrolling)
• Fairview Northland Medical Center — Princeton, Minnesota, United States (enrolling)
• Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)
• Essentia Health Sandstone — Sandstone, Minnesota, United States (enrolling)
• Sanford Thief River Falls Medical Center — Thief River Falls, Minnesota, United States (enrolling)
• Essentia Health Virginia Clinic — Virginia, Minnesota, United States (enrolling)
• MMCORC CentraCare Monticello Cancer Center — Monticello, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.